Cancer survivors and activists call out corporate greed
Organisations – including the Treatment Action Campaign (TAC), Section27 and Cancer Alliance – will join a picket on Tuesday morning in honour of cancer activist Tobeka Daki. The gathering is planned to take place outside the premises of Roche, a pharmaceutical company in Johannesburg, which has multiple patents on an essential cancer treatment drug.
Daki, a single mother from Mdantsane, succumbed to cancer in November 2016. Before her death, the activist led calls for government to make provisions for affordable and accessible cancer medication.
Daki was diagnosed with HER2 positive breast cancer in 2013 and struggled to access the drug trastuzumab – trade name Herceptin – used to treat aggressive types of cancer. Being on medical aid did not help her.
No access to trastuzumab
According to Fix the Patent Laws coalition, Daki was told by her oncologist that she needed trastuzumab in addition to chemotherapy, as this would increase her chances of beating cancer and leading a normal life. But she was not given the treatment and in 2015 the cancer came back, this time in her spine.
Roche, has more than one patent on trastuzumab, preventing the manufacturing of cheaper biosimilars that could save lives. Activists say more affordable options will not be allowed to come onto the market until 2033.
Currently the cost of a year’s treatment course on trastuzumab is over R200 000. Spokesperson for TAC Lotti Rutter says the medicine has been excluded from prescribed minimum benefits of private medical schemes because of the high costs.
TAC, a Fix the Patent Laws alliance partner, says other developing countries face similar problems in accessing affordable trastuzumab.
“In other parts of the world where the patents have expired, Roche is using different means to block access including litigating against biosimilar versions.”
High price of biosimilars
Roche says it has met with the Fix the Patent Laws on numerous occasions to share steps taken to achieve access to the drug. However the company says it does not believe that dropping patents will result in equitable access to trastuzumab and added that the discussion on patents is not relevant in the current context of increasing access to trastuzumab.
“We aim to improve access in a manner that delivers sustainable improvements to healthcare today while allowing us to continue to invest in new medical innovations,” stated a press release issued by the company.
- Watch Daki here.
On taking legal action against companies that introduced biosimilars, Roche says it has done this because it was unclear whether or not the medicines met the strict standards set for biosimilars, or if regulatory standards had been properly adhered to.
“Companies had tried to pass off our data or information as their own,” it charged.
The march is expected to take place at Illovo in Sandton from 10.30am until 1 pm. More than 50 women living with cancer are expected to be part of the picket. – Health-e News.
An edited version of this story was published on Health24.com
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Cancer survivors and activists call out corporate greed
by Masutane, Health-e News
February 7, 2017
Related
Private hospitals face nursing malpractice havoc
Nurses’ failure to follow guidelines and poor monitoring of patients is an increasing liability at private hospitals.
Professionals co-opted to support tobacco companies
The tobacco industry is spending vast sums of money to fight government’s attempts to tighten smoking laws and regulate electronic cigarettes – and it has managed to recruit some unlikely allies.
Vaping industry slams new tobacco bill
Ignorant and not based on scientific evidence. This is how vaping activists describe the latest bill on tobacco, which they say is based on fear of the unknown.